Welcome to to the second part of our post–ASCO analysis of the state of affairs in hormone receptor-positive MBC. It was not so long ago that the only options for this most common subset of breast cancer were single agent endocrine therapy and systemic chemo. We have come a long way over the last couple of decades. Today we are asking Drs. Stephanie Graff, Sara Hurvitz, and Kevin Kalinsky to talk about how they make decisions in the clinic on how to select and order treatments, specifically CDK4/6 inhibitors and the newly approved targeted therapies.
Take a listen. It is going to be an exciting discussion.
More info about the show and past episodes is available on our website: www.ourmbclife.org
Got something to share? Feedback?
Email: ourmbclife@sharecancersupport.org
Follow us on Facebook, Instagram, and twitter @ourmbclife